Monoclonal antibody-based therapies targeting PD-1 (nivolumab and pembrolizumab), PD-L1 (avelumab, atezolizumab, durvalumab) and cytotoxic T-lymphocyte antigen 4 (ipilimumab) are promising options of treatment for patients with advanced GC, and likewise the combination of these immune checkpoint inhibitors with chemotherapy, which is the subject of clinical trials [130]. The gene discussed is CD274; the disease is gastric cancer.